INTRODUCTION
Emerging infectious diseases pose a severe threat to public health due to their pathogenic, contagious nature. Quick development, validation, and implementation of precision diagnostic tests are necessary to ensure accurate detection of these infectious agents in order to ensure public safety and rapid treatment. Positive controls are a crucial component for these diagnostic assays to ensure accurate performance, but can potentially harm assay developers and laboratory end-users in their infectious state.

The key to the successful, rapid development of an infectious disease molecular diagnostic assay is to utilize non-infectious, manufactured controls. These controls should adequately represent the virus genetically and function in the appropriate assay format and sample matrix. In addition, these controls should evaluate the entire process from viral nucleic acid extraction through amplification and detection and not just a portion of the workflow (process control).

THE SAFEST, TRUE FULL-PROCESS CONTROL ON THE MARKET
SeraCare’s AccuPlex recombinant material serves as a true molecular process control for your diagnostic assays. Compatible with multiplexed RT-PCR and NGS-based assays, AccuPlex custom recombinant materials are constructed with a replication-deficient mammalian virus, producing a safe, non-infectious material (Figure 1). With a protein coat and lipid bilayer, these mammalian virus-based reference materials resemble the complexity of virus targets found in patient samples.

HIGHLIGHTS
- REAL MAMMALIAN VIRUS ENABLES FULL-PROCESS QC FOR RT-PCR BASED VIRAL DISEASE ASSAYS.
- NON-INFECTION AND REPLICATION DEFICIENT; ENSURES SAFETY DURING ASSAY DEVELOPMENT AND END-USER UTILITY.
- ACCEPTS MULTIPLE SEQUENCES FROM SAME OR DIFFERENT RNA VIRUSES; OFFERS FULL GENOME COVERAGE.

FIGURE 1: 1) RNA sequence from the pathogenic virus of interest is chosen. 2) DNA synthesis and cloning occur to produce the recombinant RNA. 3) Recombinant RNA and helper RNA are co-transfected into the mammalian cells, allowing the encapsulation of recombined RNA. 4) Exocytosis of the mature enveloped RNA virus with the RNA sequence of the virus of interest.
MOST ‘PATIENT SAMPLE-LIKE’ MATERIAL EVALUATES ENTIRE WORKFLOW

Unlike other technologies that package the viral RNA into a bacteriophage, the AccuPlex recombinant closely resembles the wild-type mammalian pathogenic virus. This enables the release of the viral genome at a similar rate to the wild-type virus during the nucleic acid sample preparation process. AccuPlex recombinant material mimics a real patient sample in your workflow, serving as a full-process control for your assay.

<table>
<thead>
<tr>
<th>Technology</th>
<th>Packaged Insert Size</th>
<th>Analyte</th>
<th>Complex Viral Structure</th>
<th>Replication Deficient</th>
<th>Flexible Sequence Design</th>
<th>True Process Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>AccuPlex</td>
<td>4 kb</td>
<td>Virus</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Cultured virus</td>
<td>Full genome</td>
<td>Virus</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>MS-2</td>
<td>1 kb</td>
<td>Bacteriophage</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

ACCUPLEX SOLVES ASSAY DEVELOPMENT CHALLENGES

If you’re developing diagnostics for emerging viral diseases and have the challenge of including safe, non-infectious controls in your test kit, partner with SeraCare’s talented R&D team to produce your custom AccuPlex recombinant virus material (DNA or RNA-based). Utilizing your sequences of interest and product specifications, we will develop a custom solution which meets your unique requirements.

SeraCare’s AccuPlex solution:
- Non-infectious and replication deficient, enables safe and effective handling of positive material
- Fully-extractable with a real viral protein coat; serves as a full-process control
- Accepts multiple sequences from same or different RNA viruses, customizable to your sequences of interest
- Digital PCR (ddPCR) QC step allows for a wide range of titer levels, offers flexible concentrations
- Compatible with any sample matrix (e.g. DBS, buffer, serum)
- Stability studies confirm product is stable at 4 °C, room temperature, and elevated temperatures

RELATED PRODUCTS

<table>
<thead>
<tr>
<th>Material #</th>
<th>Product</th>
<th>Target Regions</th>
<th>Fill Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0505-0034</td>
<td>AccuPlex Zika Reference Material</td>
<td>Entire genome</td>
<td>1 X 1.5 mL vial</td>
</tr>
<tr>
<td>0505-0001</td>
<td>AccuPlex rEbola GP/NP Reference Material</td>
<td>Glycoprotein (GP), nucleoprotein (NP) and VP24 regions</td>
<td>5 X 0.25 mL vial</td>
</tr>
<tr>
<td>2410-0327</td>
<td>AccuSpan HCV RNA Linearity Panel</td>
<td>5' UTR region</td>
<td>8 x 1.2 mL vial</td>
</tr>
<tr>
<td>2410-0318</td>
<td>AccuSpan Zika RNA Linearity Panel</td>
<td>Entire genome</td>
<td>7 x 1.5 mL vial</td>
</tr>
</tbody>
</table>

Inquire about AccuPlex recombinant products under development for chikungunya, dengue-2, MERS, and norovirus GII.

LEARN MORE

To learn more about AccuPlex Recombinant Viral Technology and SeraCare’s products for infectious disease diagnostics, visit www.seracare.com/accuplex. Contact us at +1.508.244.6400 and 800.676.1881 or email info@seracare.com.

AccuPlex™ is a trademark of SeraCare Life Sciences, Inc.
© 2018 SeraCare Life Sciences, Inc. All rights reserved.
MKT-00458-01